BOTHELL, Wash., Dec. 23, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that it has received and shipped initial retail orders for its extended-release nutritional products based on the Company’s proprietary CDT® oral drug delivery platform. The shipments represent SCOLR’s first significant direct retail sales of its nutritional products.
Stephen J. Turner, SCOLR Pharma’s President and CEO, said, “Shipment of these initial orders marks an important milestone for SCOLR as we continue to focus on growing our nutritional products business into a sustainable source of revenue. We are gratified by the response we have had with retailers and confident that our products are greeted well by consumers.”
Turner said SCOLR intends to provide investors with future updates on its nutritional business activities in conjunction with its quarterly announcements of financial results and in its periodic reports filed with the Securities and Exchange Commission.
About SCOLR Pharma:
Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.
Forward looking statements:
Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding anticipated developments in the Company’s nutritional business. Factors that could cause these forward-looking statements to differ from actual results include delays in manufacturing, labeling or shipment of products, order revisions, or variations in retailer’s marketing plans, and other risks and uncertainties discussed in the company’s periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.
Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050
SOURCE SCOLR Pharma, Inc.
